[{"address1": "80 Guest Street", "address2": "Suite 601", "city": "Boston", "state": "MA", "zip": "02135", "country": "United States", "phone": "617 500 8099", "website": "https://www.compasstherapeutics.com", "industry": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. The company was founded in 2014 and is headquartered in Boston, Massachusetts.", "fullTimeEmployees": 32, "companyOfficers": [{"maxAge": 1, "name": "Dr. Thomas J. Schuetz M.D., Ph.D.", "age": 62, "title": "Chief Executive Officer", "yearBorn": 1961, "fiscalYear": 2023, "totalPay": 835875, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Vered  Bisker-Leib M.D., MBA, Ph.D.", "age": 52, "title": "Senior Consultant", "yearBorn": 1971, "fiscalYear": 2023, "totalPay": 719000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Neil L. Lerner CPA", "age": 56, "title": "Vice President of Finance", "yearBorn": 1967, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Jonathan  Anderman J.D.", "title": "VP, Head of Legal & Corporate Secretary", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Anna  Gifford", "title": "Communications Manager", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Minori  Rosales M.D., Ph.D.", "age": 60, "title": "Senior VP & Head of Clinical Development", "yearBorn": 1963, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Karin  Herrera B.A.", "title": "VP & Head of Clinical Operations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. James  Kranz Ph.D.", "title": "VP and Head of Chemistry Manufacturing & Controls", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 3, "boardRisk": 8, "compensationRisk": 9, "shareHolderRightsRisk": 8, "overallRisk": 7, "governanceEpochDate": 1725148800, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 1.54, "open": 1.54, "dayLow": 1.48, "dayHigh": 1.61, "regularMarketPreviousClose": 1.54, "regularMarketOpen": 1.54, "regularMarketDayLow": 1.48, "regularMarketDayHigh": 1.61, "beta": 0.708, "forwardPE": -2.9215686, "volume": 723072, "regularMarketVolume": 723072, "averageVolume": 434396, "averageVolume10days": 452990, "averageDailyVolume10Day": 452990, "bid": 1.48, "ask": 1.53, "bidSize": 400, "askSize": 100, "marketCap": 205007600, "fiftyTwoWeekLow": 0.765, "fiftyTwoWeekHigh": 2.34, "priceToSalesTrailing12Months": 241.18541, "fiftyDayAverage": 1.08716, "twoHundredDayAverage": 1.483115, "currency": "USD", "enterpriseValue": 66748324, "floatShares": 88570277, "sharesOutstanding": 137588992, "sharesShort": 1782964, "sharesShortPriorMonth": 2024486, "sharesShortPreviousMonthDate": 1721001600, "dateShortInterest": 1723680000, "sharesPercentSharesOut": 0.012999999, "heldPercentInsiders": 0.12041, "heldPercentInstitutions": 0.72080004, "shortRatio": 3.89, "shortPercentOfFloat": 0.0183, "bookValue": 1.062, "priceToBook": 1.4030131, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -47242000, "trailingEps": -0.35, "forwardEps": -0.51, "enterpriseToRevenue": 78.527, "enterpriseToEbitda": -1.225, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "CMPX", "underlyingSymbol": "CMPX", "shortName": "Compass Therapeutics, Inc.", "longName": "Compass Therapeutics, Inc.", "firstTradeDateEpochUtc": 1617629400, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "2da7fead-7fe9-351a-a396-4dd759234d3a", "gmtOffSetMilliseconds": -14400000, "currentPrice": 1.49, "targetHighPrice": 10.0, "targetLowPrice": 5.0, "targetMeanPrice": 8.0, "targetMedianPrice": 8.0, "recommendationMean": 1.6, "recommendationKey": "buy", "numberOfAnalystOpinions": 6, "totalCash": 146227008, "totalCashPerShare": 1.063, "ebitda": -54501000, "totalDebt": 1088000, "quickRatio": 15.381, "currentRatio": 16.151, "totalRevenue": 850000, "debtToEquity": 0.745, "revenuePerShare": 0.006, "returnOnAssets": -0.20583999, "returnOnEquity": -0.30053, "freeCashflow": -23758500, "operatingCashflow": -42918000, "grossMargins": 1.0, "operatingMargins": -17.7, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-09-05"}]